MiMedx Group (NASDAQ:MDXG) Price Target Lowered to $10.00 at Lake Street Capital

MiMedx Group (NASDAQ:MDXG) had its price objective reduced by Lake Street Capital from $12.00 to $10.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Lake Street Capital’s price target suggests a potential upside of 86.74% from the company’s previous close.

Other analysts have also recently issued reports about the stock. Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Mizuho decreased their price target on MiMedx Group from $12.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, December 17th. Finally, Wall Street Zen upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $10.67.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG traded down $0.07 during mid-day trading on Tuesday, hitting $5.36. The stock had a trading volume of 862,977 shares, compared to its average volume of 1,068,299. The company has a 50 day moving average of $6.75 and a two-hundred day moving average of $6.91. MiMedx Group has a twelve month low of $5.13 and a twelve month high of $9.36. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.95 and a current ratio of 4.41. The firm has a market cap of $793.08 million, a PE ratio of 19.83 and a beta of 1.57.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, October 29th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.08. MiMedx Group had a return on equity of 27.19% and a net margin of 10.38%.The business had revenue of $113.73 million for the quarter, compared to analyst estimates of $94.74 million. Research analysts predict that MiMedx Group will post 0.3 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Kimberly Maersk-Moller sold 58,300 shares of MiMedx Group stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the sale, the insider directly owned 236,982 shares in the company, valued at approximately $1,758,406.44. The trade was a 19.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.70% of the company’s stock.

Institutional Trading of MiMedx Group

A number of institutional investors have recently made changes to their positions in MDXG. Divisadero Street Capital Management LP lifted its holdings in MiMedx Group by 362.9% in the 2nd quarter. Divisadero Street Capital Management LP now owns 223,220 shares of the company’s stock valued at $1,364,000 after purchasing an additional 175,000 shares in the last quarter. Truist Financial Corp lifted its stake in shares of MiMedx Group by 80.8% in the second quarter. Truist Financial Corp now owns 96,250 shares of the company’s stock worth $588,000 after buying an additional 43,000 shares in the last quarter. HB Wealth Management LLC purchased a new position in MiMedx Group in the 2nd quarter worth approximately $156,000. Trigran Investments Inc. boosted its holdings in shares of MiMedx Group by 10.4% during the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock worth $51,266,000 after purchasing an additional 790,901 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of MiMedx Group in the second quarter valued at approximately $268,000. 79.15% of the stock is owned by institutional investors and hedge funds.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.